End stage kidney disease under hemodialysis. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: Administration of 50 mg zinc sulfate tablets - once a day - orally - for one month - manufactured by Alhawi company. Intervention 2: Control group: Administration o
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People over 18 years old Zinc level less than 70 mcg/ dL Has been on regular hemodialysis for at least 6 month Undergo hemodialysis at least twice a week
Exclusion criteria
Exclusion criteria: Patient dissatisfaction Have been hospitalized for the last 3 months Use of zinc supplement in the last two weeks (use of specific multivitamins for dialysis patients is not recommended) Use of selenium supplement in the last two weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of zinc supplementation on CRP. Timepoint: The beginning of the study, 30 and 60 days. Method of measurement: Laboratory test. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of zinc supplementation on NLR (nutrophil,lymphocyte ratio). Timepoint: The beginning of the study, day 30 and 60. Method of measurement: laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShayan Mastoor Tehrani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed